Clinical Trials Logo

Filter by:
NCT ID: NCT01865084 Terminated - Clinical trials for Muscular Dystrophy, Duchenne

A Study of Tadalafil for Duchenne Muscular Dystrophy

Start date: September 2013
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to determine if tadalafil can slow the decline in walking ability of boys who have Duchenne muscular dystrophy (DMD). The study will also assess the safety of tadalafil and any side effects that might be associated with it in boys who have DMD. Participants will receive study treatment (tadalafil or placebo) for the first 48 weeks of the study, and can then continue into an open label extension (OLE) that consists of two periods during which all participants will receive tadalafil. In OLE period 1, all participants will receive tadalafil for 48 weeks. Participants completing OLE period 1 will continue into OLE period 2 and will receive tadalafil for at least another 48 weeks.

NCT ID: NCT01861977 Completed - Health Behavior Clinical Trials

Healthy Habits Program for High Cardiovascular Risk Patients: Randomized Controlled Clinical Trial

Start date: June 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effectiveness of a program to improve habits in a population with cardiovascular disease, comparing two different educational techniques (cognitive behavioral therapy group vs. informational workshops).

NCT ID: NCT01861236 Completed - Clinical trials for Advanced Hormone Dependent Prostate Cancer

Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina

FAST AR
Start date: March 2013
Phase:
Study type: Observational [Patient Registry]

Prospective, observational study to collect and analyze data on patients with advanced hormone dependent prostate cancer treated with Firmagon® according to routine medical practice in Argentina

NCT ID: NCT01860976 Completed - Psoriatic Arthritis Clinical Trials

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis

ASTRAEA
Start date: June 17, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare subcutaneous Abatacept to placebo in the treatment of psoriatic arthritis

NCT ID: NCT01860066 Withdrawn - Clinical trials for Chronic Obstructive Pulmonary Disease

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Start date: December 2013
Phase: Phase 3
Study type: Interventional

Study is to show that QVA149 is superior to the standard of care, fluticasone/salmeterol, in patients with moderate to severe airflow limitation.

NCT ID: NCT01856504 Completed - Clinical trials for Coronary Artery Disease

Validation of an Intracycle CT Motion CORrection Algorithm for Diagnostic AccuracY

VICTORY
Start date: May 2013
Phase: N/A
Study type: Observational [Patient Registry]

To demonstrate the incremental utility of SSF for individuals undergoing CCTA, with expected improvements in image quality and diagnostic accuracy.

NCT ID: NCT01856309 Completed - Clinical trials for Arthritis, Rheumatoid

Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003

SIRROUND-LTE
Start date: August 7, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety and efficacy of CNTO 136 (sirukumab) in participants with rheumatoid arthritis (RA) who are unresponsive to treatment with modifying antirheumatic drugs (DMARDs) or anti-TNF alpha agents.

NCT ID: NCT01855750 Completed - Lymphoma Clinical Trials

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Start date: September 3, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate if ibrutinib administered in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the clinical outcome in newly diagnosed patients with non-germinal center B-cell subtype (GCB) of diffuse large B-cell lymphoma (DLBCL) selected by immunohistochemistry (IHC) or newly diagnosed patients with activated B cell-like (ABC) subtype of DLBCL identified by gene expression profiling (GEP) or both populations.

NCT ID: NCT01854047 Completed - Asthma Clinical Trials

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

Start date: June 2013
Phase: Phase 2
Study type: Interventional

Primary Objective: To evaluate the efficacy of different doses and regimens of dupilumab in patients with moderate to severe uncontrolled asthma Secondary Objective: To evaluate different doses and regimens of dupilumab in patients with moderate to severe uncontrolled asthma, with regard to: - Safety and tolerability - Dupilumab systemic exposure and anti-drug antibodies

NCT ID: NCT01852617 Completed - Pregnancy Clinical Trials

A Smoking Cessation Intervention During Pregnancy in Argentina and Uruguay

Start date: October 2011
Phase: N/A
Study type: Interventional

Argentina and Uruguay are among the countries with the highest proportion of pregnant women who smoke. The implementation of an effective smoking cessation intervention would have a significant impact on the health of mothers and children. The "5 A's" (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider, which is considered the standard of care worldwide. However, it is under used in Argentina and Uruguay. We will conduct a two-arm, parallel cluster randomized controlled trial of an implementation intervention in 20 prenatal clinics in Argentina and Uruguay. Our primary hypothesis is that the intervention is feasible in prenatal clinics in Argentina and Uruguay and will increase the frequency of women receiving tobacco use cessation counseling during pregnancy. Our secondary hypothesis is that the intervention will decrease the frequency of women who smoke by the end of their pregnancies. Prenatal clinics will be randomly allocated to either an intervention or a control group after a baseline data collection period. Midwife facilitators in the ten intervention clinics will be identified and trained to deliver the "5 A's" to pregnant women and will then disseminate and implement the program. The ten clinics in the control group will continue with their standard in-service activities. A follow-up data collection will be conducted immediately after delivery. The intervention will be tailored by formative research to be readily applicable to local prenatal care services at busy maternity hospitals, as well as to be acceptable to local pregnant women and health providers. The study will be conducted in 48 months.